Loading
SRD5A3 (Polyprenal reductase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
Plays a key role in early steps of protein N-linked glycosylation by being involved in the conversion of polyprenol into dolichol. Acts as a polyprenal reductase that mediates the reduction of polyprenal into dolichal in a NADP-dependent mechanism. Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.93, genetic association 0.00, clinical 0.96).
In plain words · SRD5A3 (Polyprenal reductase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
SRD5A3 (Polyprenal reductase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
Plays a key role in early steps of protein N-linked glycosylation by being involved in the conversion of polyprenol into dolichol.
No product in this corpus aims at SRD5A3 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA SRD5A3: RNA low tissue specificity; no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Prostate cancer); Open Targets associates it with 3 specific cancer types at or above 0.5 (benign prostatic hyperplasia, prostate cancer, prostate carcinoma); the corpus evidence decides and the Open Targets list is quoted for comparison. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas SRD5A3 tissue; Open Targets ENSG00000128039 associations
First described 2004. Earliest sequence paper UniProt cites for the protein: Ota et al, Nat. Genet, 2004, "Complete sequencing and characterization of 21,243 full-length human cDNAs". Source.
Sources: HGNC HGNC:25812 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9H8P0 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000128039 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: prostate cancer 0.59 (GraphQL API, CC0))
Plays a key role in early steps of protein N-linked glycosylation by being involved in the conversion of polyprenol into dolichol. Acts as a polyprenal reductase that mediates the reduction of polyprenal into dolichal in a NADP-dependent mechanism. Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation. Also able to convert testosterone (T) into 5-alpha-dihydrotestosterone (DHT). Location: Endoplasmic reticulum membrane (UniProt). Locus 4q12 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer stained high; medium in carcinoid, endometrial cancer, glioma, lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SRD5A3" OR ABSTRACT:"SRD5A3" OR TITLE:"steroid 5 alpha-reductase 3" OR ABSTRACT:"steroid 5 alpha-reductase 3" OR TITLE:"Polyprenal reductase" OR ABSTRACT:"Polyprenal reductase" OR TITLE:"FLJ13352" OR ABSTRACT:"FLJ13352" OR TITLE:"SRD5A2L" OR ABSTRACT:"SRD5A2L" OR TITLE:"SRD5A2L1" OR ABSTRACT:"SRD5A2L1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SRD5A3, not a curated reading list.